TW200621307A - Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion - Google Patents

Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion

Info

Publication number
TW200621307A
TW200621307A TW094138786A TW94138786A TW200621307A TW 200621307 A TW200621307 A TW 200621307A TW 094138786 A TW094138786 A TW 094138786A TW 94138786 A TW94138786 A TW 94138786A TW 200621307 A TW200621307 A TW 200621307A
Authority
TW
Taiwan
Prior art keywords
solid dispersion
pranlukast
improved
composition
bioavailibility
Prior art date
Application number
TW094138786A
Other languages
Chinese (zh)
Other versions
TWI380829B (en
Inventor
Joon-Gyo Oh
Yong-Ho Oh
Ho-Chul Shin
Ji-Sun Jung
Key-An Um
Dong-Sun Min
Nam-Kyu Lee
Ju-Young Lee
Guang-Jin Im
Tae-Kon Kim
Jeong-Tae Kim
Woo-Jae Jang
Dong-Chul Shin
Woong-Sik Kim
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36319405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200621307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of TW200621307A publication Critical patent/TW200621307A/en
Application granted granted Critical
Publication of TWI380829B publication Critical patent/TWI380829B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed is a pranlukast solid dispersion composition with an improved and a method of manufacturing the same. More particularly, the present invention provides a pranlukast solid dispersion manufactured by a hot-melting process using a composition comprising pranlukast and at least one water-soluble polymer selected from the group consisting of polyvinylpyrrolidone vinylacetate copolymer, polyvinylpyrrolidone and polyvinylalcohol, which has greatly improved dissolution rate and bioavailability as compared to those prepared by the conventional spray-drying method, thus enabling to obtain the equivalent pharmaceutical effects with less amount of a drug.
TW094138786A 2004-11-04 2005-11-04 Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion TWI380829B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040089455A KR101086254B1 (en) 2004-11-04 2004-11-04 Soild dispersion composition of pranlukast with improved bioavailability and the method of preparing the solid dispersion

Publications (2)

Publication Number Publication Date
TW200621307A true TW200621307A (en) 2006-07-01
TWI380829B TWI380829B (en) 2013-01-01

Family

ID=36319405

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094138786A TWI380829B (en) 2004-11-04 2005-11-04 Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion

Country Status (6)

Country Link
JP (1) JP5232472B2 (en)
KR (1) KR101086254B1 (en)
AR (1) AR051758A1 (en)
MX (1) MX2007005427A (en)
TW (1) TWI380829B (en)
WO (1) WO2006049433A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101233235B1 (en) * 2005-08-26 2013-02-15 에스케이케미칼주식회사 Pharmaceutical composition of pranlukast solid-dispersion with improved early dissolution rate and the method of preparing the composition
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
CA3076115C (en) * 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
KR101381881B1 (en) * 2012-03-12 2014-04-04 충남대학교산학협력단 Preparation method of Pranlukast nano solid dispersant with high solubility and release rate
KR101446129B1 (en) * 2012-10-10 2014-10-06 조선대학교산학협력단 Process for preparing pranlukast-containing solid formulation
KR102191562B1 (en) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 Solid dispersions of insoluble drug and preparation method therof
KR102363727B1 (en) 2015-06-01 2022-02-16 삼아제약 주식회사 Composition for preparing solid formulation containing pranlukast having enhanced bioavailability and production method thereof
US12036214B2 (en) 2018-07-13 2024-07-16 Council Of Scientific And Industrial Research [In/In] Solid dispersion comprising an anticancer compound for improved solubility and efficacy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509807A1 (en) * 1995-03-21 1996-09-26 Basf Ag Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method
DE69625813T2 (en) * 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka GRANULA CONTAINING PRANLUKAST, METHOD FOR PRODUCING THE GRANULA AND METHOD FOR REDUCING THE BAKING-UP OF PRANLUKAST
US5858509A (en) * 1996-11-15 1999-01-12 Digital Equipment Corporation Attenuating vibrations in a mounting shelf for multiple disk drives
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100381834B1 (en) * 2000-05-20 2003-04-26 이상득 Solid dispersion system of pranlukast with improved dissolution, and the method thereof
UA80393C2 (en) 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix

Also Published As

Publication number Publication date
MX2007005427A (en) 2012-10-02
JP2008519067A (en) 2008-06-05
KR101086254B1 (en) 2011-11-24
WO2006049433A1 (en) 2006-05-11
AR051758A1 (en) 2007-02-07
KR20060040211A (en) 2006-05-10
JP5232472B2 (en) 2013-07-10
TWI380829B (en) 2013-01-01

Similar Documents

Publication Publication Date Title
TW200621307A (en) Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion
WO2006125620A3 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
MX2022002952A (en) Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phen oxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]- 4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2006137855A3 (en) Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
WO2006089674A3 (en) Tablets with improved drug substance dispersibility
MY177386A (en) Drug formulations having improved pharmacokinetic properties
WO2011077451A3 (en) Controlled release pharmaceutical composition
MX2009002757A (en) Abuse resistant drug formulation.
WO2006113631A3 (en) Bioenhanced compositions
WO2005117843A3 (en) Sustained release preparations
WO2009041643A1 (en) Method of modifying isoelectric point of antibody via amino acid substitution in cdr
WO2008070072A3 (en) Carvedilol forms, compositions, and methods of preparation thereof
WO2014081581A3 (en) Highly loaded amorphous efavirenz composition and process for preparing the same
WO2008048469A3 (en) Controlled-release coated dosage forms containing galantamine
WO2007144169A3 (en) Entacapone-derivatives
WO2009028900A3 (en) Oral administration drug comprising clopidogrel besylate
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2005084636A3 (en) A process for the preparation of controlled-release pharmaceutical composition of metoprolol
WO2006123243A3 (en) Pharmaceutical dosage forms comprising escitalopram in form of granules
WO2005007074A3 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
WO2002094215A3 (en) Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
RU2019138248A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, CONTAINING ENZALUTAMIDE
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
EA201071024A1 (en) MIXTURE FOR OBTAINING QUICKLY DESTRUCTIVE TABLETS

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees